Role of biomarkers in cardioncology

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Cardiotoxicity is a serious adverse effect of anticancer drugs, impacting on quality of life and overall survival of cancer patients. According to the current standard for monitoring cardiac function, cardiotoxicity is usually detected only when a functional impairment has already occurred, precluding any chance of preventing its development. Over the last decade, however, a new approach, based on the use of cardiac biomarkers, has emerged, and has proven to be an effective alternative strategy for early detection of subclinical cardiac injury. In particular, the role of troponin I in identifying patients at risk of cardiotoxicity and of angiotensin-converting enzyme inhibitors in preventing left ventricular ejection fraction reduction and late cardiac events represent an effective tool for the prevention of this complication.

Original languageEnglish
Pages (from-to)1937-1948
Number of pages12
JournalClinical Chemistry and Laboratory Medicine
Volume49
Issue number12
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Troponin I
Biomarkers
Angiotensin-Converting Enzyme Inhibitors
Monitoring
Pharmaceutical Preparations
Stroke Volume
Quality of Life
Survival
Wounds and Injuries
Cardiotoxicity
Neoplasms

Keywords

  • Biomarkers
  • Cardioncology
  • Cardiotoxicity
  • Chemotherapy
  • Left ventricular dysfunction

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Role of biomarkers in cardioncology. / Cardinale, Daniela; Salvatici, Michela; Sandri, Maria T.

In: Clinical Chemistry and Laboratory Medicine, Vol. 49, No. 12, 12.2011, p. 1937-1948.

Research output: Contribution to journalArticle

@article{85c939a0bf444fcea1ad9942398244c7,
title = "Role of biomarkers in cardioncology",
abstract = "Cardiotoxicity is a serious adverse effect of anticancer drugs, impacting on quality of life and overall survival of cancer patients. According to the current standard for monitoring cardiac function, cardiotoxicity is usually detected only when a functional impairment has already occurred, precluding any chance of preventing its development. Over the last decade, however, a new approach, based on the use of cardiac biomarkers, has emerged, and has proven to be an effective alternative strategy for early detection of subclinical cardiac injury. In particular, the role of troponin I in identifying patients at risk of cardiotoxicity and of angiotensin-converting enzyme inhibitors in preventing left ventricular ejection fraction reduction and late cardiac events represent an effective tool for the prevention of this complication.",
keywords = "Biomarkers, Cardioncology, Cardiotoxicity, Chemotherapy, Left ventricular dysfunction",
author = "Daniela Cardinale and Michela Salvatici and Sandri, {Maria T.}",
year = "2011",
month = "12",
doi = "10.1515/CCLM.2011.692",
language = "English",
volume = "49",
pages = "1937--1948",
journal = "Clinical Chemistry and Laboratory Medicine",
issn = "1434-6621",
publisher = "Walter de Gruyter GmbH",
number = "12",

}

TY - JOUR

T1 - Role of biomarkers in cardioncology

AU - Cardinale, Daniela

AU - Salvatici, Michela

AU - Sandri, Maria T.

PY - 2011/12

Y1 - 2011/12

N2 - Cardiotoxicity is a serious adverse effect of anticancer drugs, impacting on quality of life and overall survival of cancer patients. According to the current standard for monitoring cardiac function, cardiotoxicity is usually detected only when a functional impairment has already occurred, precluding any chance of preventing its development. Over the last decade, however, a new approach, based on the use of cardiac biomarkers, has emerged, and has proven to be an effective alternative strategy for early detection of subclinical cardiac injury. In particular, the role of troponin I in identifying patients at risk of cardiotoxicity and of angiotensin-converting enzyme inhibitors in preventing left ventricular ejection fraction reduction and late cardiac events represent an effective tool for the prevention of this complication.

AB - Cardiotoxicity is a serious adverse effect of anticancer drugs, impacting on quality of life and overall survival of cancer patients. According to the current standard for monitoring cardiac function, cardiotoxicity is usually detected only when a functional impairment has already occurred, precluding any chance of preventing its development. Over the last decade, however, a new approach, based on the use of cardiac biomarkers, has emerged, and has proven to be an effective alternative strategy for early detection of subclinical cardiac injury. In particular, the role of troponin I in identifying patients at risk of cardiotoxicity and of angiotensin-converting enzyme inhibitors in preventing left ventricular ejection fraction reduction and late cardiac events represent an effective tool for the prevention of this complication.

KW - Biomarkers

KW - Cardioncology

KW - Cardiotoxicity

KW - Chemotherapy

KW - Left ventricular dysfunction

UR - http://www.scopus.com/inward/record.url?scp=84856534493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856534493&partnerID=8YFLogxK

U2 - 10.1515/CCLM.2011.692

DO - 10.1515/CCLM.2011.692

M3 - Article

C2 - 21892906

AN - SCOPUS:84856534493

VL - 49

SP - 1937

EP - 1948

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

SN - 1434-6621

IS - 12

ER -